Key result
Coadministered amlodipine and atorvastatin produced statistically significant reductions in systolic blood pressure and LDL cholesterol without adverse pharmacodynamic interaction.
Why the study?
Does coadministration of amlodipine and atorvastatin reduce systolic blood pressure and low-density lipoprotein cholesterol without adverse pharmacodynamic interactions in patients with concomitant hypertension and dyslipidemia?
RCT (n=1,660)
Placebo-controlled
3 x 5 factorial
Does coadministration of amlodipine and atorvastatin reduce systolic blood pressure and low-density lipoprotein cholesterol without adverse pharmacodynamic interactions in patients with concomitant hypertension and dyslipidemia?
Coadministration of amlodipine and atorvastatin effectively lowers both blood pressure and LDL-C without adverse pharmacodynamic interactions, supporting the use of single-pill combinations for cardiovascular risk management.
Supports single-pill amlodipine-atorvastatin combinations in comorbid hypertension and dyslipidemia; extends evidence for fixed-dose dual therapy.
Guidelines stress the importance of the simultaneous management of multiple cardiovascular risk factors. This can in part be achieved by coadministration of lipid-lowering and antihypertensive treatments. Potential pharmacodynamic interaction between drugs should be investigated as part of developing single-pill combinations. The Respond trial assessed whether combining amlodipine to treat hypertension and atorvastatin to treat dyslipidemia affected the action of either monotherapy. A total of 1660 hypertensive patients with dyslipidemia received 1 of 15 combinations of amlodipine (placebo, 5, or 10 mg) and atorvastatin (placebo, 10, 20, 40, or 80 mg) in a 3 x 5 factorial randomized, placebo-controlled design. At 8 weeks, combination-treated patients experienced dose-related and statistically significant reductions in systolic blood pressure, low-density lipoprotein cholesterol, and Framingham risk score. Overall, coadministered atorvastatin and amlodipine was well tolerated and without adverse pharmacodynamic interaction; combination treatment did not affect the low-density lipoprotein cholesterol-lowering efficacy and safety of atorvastatin, or the systolic blood pressure-lowering efficacy and safety of amlodipine.
No takes yet. Share an insight, caveat, or question.
Preston et al. (2007) conducted an RCT in Hypertension and dyslipidemia (n=1,660). Amlodipine and Atorvastatin vs. Placebo and monotherapies was evaluated on Reductions in systolic blood pressure, low-density lipoprotein cholesterol, and Framingham risk score. Coadministered amlodipine and atorvastatin produced statistically significant reductions in systolic blood pressure and LDL cholesterol without adverse pharmacodynamic interaction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: